ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Efficacy of Telitacicept in Childhood-Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting-Adjusted Comparison to a Historical Control Group Treated With Belimumab.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pathogenesis, Treatment Advances, and Renal Outcomes in Childhood-Onset Lupus Nephritis.Clinical pediatrics · 2026Review
- Defective efferocytosis in diabetes: molecular mechanisms and emerging therapeutic strategies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- Novel use of telitacicept in primary immune thrombocytopenia: a case report.BMC pediatrics · 2026Article
- Case Report: Telitacicept in the treatment of refractory juvenile idiopathic arthritis: clinical experience from three cases.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveThe therapeutic effects of telitacicept combined with standard of care (SoC) in childhood-onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
methodsWe performed a prospective cohort study across seven tertiary hospitals in China, enrolling patients aged 5 to 18 years with cSLE. Primary endpoints included the proportions of patients attaining Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) at 3, 6, and 12 months after treatment, complemented by relapse rates and steroid tapering metrics. Propensity score-based inverse probability of treatment weighting (IPTW) was employed to address baseline imbalances between the telitacicept group (n = 60) and the historical control group treated with belimumab (n = 67).
resultsAmong 60 enrolled patients (median follow-up 12 [interquartile range 6-12] months), LLDAS and DORIS achievement rates progressively increased from 19.6% and 7.8% at 6 months to 65.7% and 37.1% at 12 months. Flare rates remained low (3 months: 1.7%; 6 months: 11.8%; 12 months: 14.3%). Notably, 74.3% of patients achieved prednisone doses ≤7.5 mg/day by 12 months (vs baseline 13.3%, P < 0.0001). IPTW-adjusted analyses demonstrated comparable efficacy between the telitacicept and belimumab groups across all endpoints in terms of LLDAS and DORIS attainment, steroid reduction, and immunologic normalization (all P > 0.05).
conclusionTelitacicept combined with SoC exhibited significant improvements in disease activity, steroid reduction, and immunologic markers, with therapeutic outcomes comparable to belimumab in cSLE management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.